Biolegend, 127662, Ultra-LEAF™ Purified anti-mouse Ly-6G Antibody, 100mg

Lymphocyte antigen 6 complex, locus G (Ly-6G), a 21-25 kD GPI-anchored protein, is expressed on the majority of myeloid cells in bone marrow and peripheral granulocytes.
100mg
Verified Reactivity: Mouse
Antibody Type: Monoclonal
Host Species: Rat
Immunogen: Ly-6G transfected EL-4J cell line.
Formulation: 0.2 µm filtered in phosphate-buffered solution, pH 7.2, containing no preservative.
Endotoxin Level: Less than 0.01 EU/µg of the protein (< 0.001 ng/µg of the protein) as determined by the LAL test.
Preparation: The Ultra-LEAF™ (Low Endotoxin, Azide-Free) antibody was purified by affinity chromatography.
Concentration: The antibody is bottled at the concentration indicated on the vial, typically between 2 mg/mL and 3 mg/mL. Older lots may have also been bottled at 1 mg/mL. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C. This Ultra-LEAF™ solution contains no preservative; handle under aseptic conditions.
Application: FC - Quality tested Depletion, IHC - Reported in the literature, not verified in house
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume or 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.
Application Notes: While 1A8 recognizes only Ly-6G, clone RB6-8C5 recognizes both Ly-6G and Ly-6C. Clone RB6-8C5 binds with high affinity to mouse Ly-6G molecules and to a lower extent to Ly-6C15. Clone RB6-8C5 impairs the binding of anti-mouse Ly-6G clone 1A815. However, clone RB6-8C5 is able to stain in the presence of anti-mouse Ly-6C clone HK1.416. Additional reported applications (for the relevant formats) include: immunohistochemistry9 of frozen sections10 and paraffin-embedded sections11, depletion4, 12-14, and spatial biology (IBEX)20,21. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for in vivo studies or highly sensitive assays (Cat. No. 127632, 127649, 127650, 127661 and 127662).
Application References(PubMed link indicates BioLegend citation): Fleming TJ, et al. 1993. J. Immunol. 151:2399. (FC) Daley JM, et al. 2008. J. Leukocyte Biol. 83:1. (FC) Dietlin TA, et al. 2007. J. Leukocyte Biol. 81:1205. (FC) Daley J, et al. 2007. J. Leukocyte Biol. doi:10.1189. (Deplete) PubMed Tadagavadi RK, et al. 2010. J. Immunol. 185:4904. PubMed Sumagin R, et al. 2010. J. Immunol. 185:7057. PubMed Guiducci C, et al. 2010. J. Exp Med. 207:2931. PubMed Fujita M, et al. 2011. Cancer Res. 71:2664. PubMed Van Leeuwen, et al. 2008. Arterioscler. Thromb. Vasc. Biol. 28:84. (IHC) Kowanetz M, et al. 2010. P. Natl. Acad. Sci. USA 107:21248. [supplementary data] (IHC) Esbona K, et al. 2016. Breast Cancer Res. 18:35. (IHC) Wojtasiak M, et al. 2010. J. Gen. Virol. 91:2158. (FC, Deplete) Jaeger BN, et al. 2012. J. Exp. Med. 209:565. (Deplete) Wozniak KL, et al. 2012. BMC Immunol. 13:65 (FC, Deplete) Ribechini E, et al. 2009. Eur. J. Immunol. 39:3538. Ng LG, et al. 2011. J Invest. Dermatol. 131:2058. PubMed Ma C, et al. 2012. J. Leukoc. Biol. 92:1199. McCartney-Francis, N, et al. 2014. J Leukoc. Biol. 96:917. PubMed Her Z, et al. 2014. EMBO Mol. Med. 7:24. PubMed Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations: Banka AL, et al. 2023. Nat Commun. 14:2462. PubMed Li Y, et al. 2023. Theranostics. 13:403. PubMed Pernet E, et al. 2023. Nature. 614:530. PubMed Haffner-Luntzer M, et al. 2023. Front Immunol. 14:1074207. PubMed Haffner–Luntzer M, et al. 2019. Proc Natl Acad Sci U S A. 116:8615. PubMed Gawish R, et al. 2022. Elife. 11:. PubMed Deng H, et al. 2021. J Immunother Cancer. 9: . PubMed Prystaz K, et al. 2018. Am J Pathol. 188:474. PubMed Mödinger Y, et al. 2018. Am J Pathol. 189:147. PubMed Kaiser R, et al. 2021. JCI Insight. 6:e150862. PubMed Kuhn MR, et al. 2022. Front Endocrinol (Lausanne). 13:997745. PubMed Hu J, et al. 2022. J Immunol Res. 2022:7966089. PubMed Pan YC, et al. 2021. Mol Ther Oncolytics. 20:175. PubMed Shang Q, et al. 2020. Cell Death Dis. 0.949305556. PubMed Kim AD, et al. 2021. Sci Rep. 11:24194. PubMed Fischer V, et al. 2022. J Bone Miner Res. 37:137. PubMed Bergdolt S, et al. 2017. PLoS One. 12(6):e0179512. PubMed Wang T et al. 2018. Immunity. 49(3):504-514 . PubMed Liu YG, et al. 2019. FASEB J. 33:5018. PubMed Zheng Z, et al. 2021. Nat Commun. 12:6202. PubMed Chen J, et al. 2021. J Invest Dermatol. 787:141. PubMed Calvente CJ, et al. 2019. J Clin Invest. 130:4091. PubMed Kaiser K, et al. 2018. Naunyn Schmiedebergs Arch Pharmacol. 391:523. PubMed Kemmler J, et al. 2016. PLoS One. 10: 0131194. PubMed
RRID: AB_2860669 (BioLegend Cat. No. 127680) AB_11150581 (BioLegend Cat. No. 127632) AB_2572001 (BioLegend Cat. No. 127649) AB_2572002 (BioLegend Cat. No. 127650) AB_2860668 (BioLegend Cat. No. 127661) AB_2860669 (BioLegend Cat. No. 127662)
Structure: A 21-35 kD GPI-anchorded membrane protein
Distribution: Expressed on the majority of myeloid cells in bone marrow and peripheral granulocytes. The monoclonal antibody RB6-8C5 recognizes both Ly-6G and Ly-6C.
Cell Type: Granulocytes, Macrophages, Monocytes
Biology Area: Immunology, Innate Immunity
Antigen References: Fleming TJ, et al. 1993. J. Immunol. 151:2399.
Gene ID: 546644
UniProt: View information about Ly-6G on UniProt.org
Clone: 1A8
Regulatory Status: RUO
Other Names: Lymphocyte antigen 6 complex, locus G
Isotype: Rat IgG2a, κ
Q: Do you guarantee that your antibodies are totally pathogen free?
A: BioLegend does not test for pathogens in-house aside from the GoInVivo™ product line. However, upon request, this can be tested on a custom basis with an outside, independent laboratory.
Q: Does BioLegend test each Ultra-LEAF™ antibody by functional assay?
A: No, BioLegend does not test Ultra-LEAF™ antibodies by functional assays unless otherwise indicated. Due to the possible complexities and variations of uses of biofunctional antibodies in different assays and because of the large product portfolio, BioLegend does not currently perform functional assays as a routine QC for the antibodies. However, we do provide references in which the antibodies were used for functional assays and we do perform QC to verify the specificity and quality of the antibody based on our strict specification criteria.
Q: Does BioLegend test each Ultra-LEAF™ antibody for potential pathogens?
A: No, BioLegend does not test for pathogens in-house unless otherwise indicated.  However, we can recommend an outside vendor to perform this testing as needed.
Q: Have you tested this Ultra-LEAF™ antibody for in vivo or in vitro applications?
A: We don't test our antibodies for in vivo or in vitro applications unless otherwise indicated. Depending on the product, the TDS may describe literature supporting usage of a particular product for bioassay. It may be best to further consult the literature to find clone specific information.